Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Pā¦ (NCT06524739) | Clinical Trial Compass
TerminatedPhase 3
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
Stopped: Sponsor decision, not for safety reasons.
United States16 participantsStarted 2024-08-28
Plain-language summary
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 \[COVID-19\] POTS \[post-COVID-POTS\]).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Provide written informed consent and be willing and, in the opinion of the investigator, able to adhere to all protocol requirements.
ā. Males and females aged ā„ 18 at the time of providing written informed consent.
ā. Diagnosis of post-COVID POTS, defined by both a preceding COVID-19 infection based on confirmed historical documentation and onset of POTS symptoms developing within 4 months after COVID-19 infection as defined per consensus criteria.
ā. COMPASS-31 score of at least 40 at the Screening visit.
ā. Positive confirmatory standardized standing test (ie, HR increase of ā„ 30 bpm \[ā„ 40 bpm for participants aged 18 to 19 years\] within 10 minutes in the absence of orthostatic hypotension) at the Screening visit.
Exclusion criteria
ā. Treatment with Immunoglobulin G (IgG) or plasmapheresis within 12 weeks before Screening
ā. Symptoms and / or diagnosis of or receiving treatment for POTS before COVID-19 infection
ā. Prior diagnosis of or receiving current treatment at Screening for the following conditions (unless onset was related to the inciting POTS-associated COVID-19 infection): certain neurologic, autoimmune, endocrine, cardiac, or other disorders, and pre-existing psychiatric disorders
What they're measuring
1
Proportion of Participants No Longer Meeting Diagnostic Criteria of Post-COVID POTS as Measured by Standardized Standing Test (ie, No Longer Experiencing HR Increase of ā„30 Bpm, in the Absence of 20 mmHg Decrease of SBP [Orthostatic Hypotension])
ā. Presence of active infections, including human immunodeficiency virus infection, hepatitis B, hepatitis C, active SARS-CoV-2 infection, or any uncontrolled systemic infection